← Back to Search

Adherence Strategies for Lung Cancer Screening

N/A

Recruiting

Led By Katharine Rendle, PhD,MSW,MPH

Research Sponsored by Abramson Cancer Center at Penn Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients eligible for LCS based on 2021 US Preventive Services Task Force (USPSTF) population guidelines (aged 50-80; smoking history of 20-pack years; smoked within the last 15 years)

Patients who have not been diagnosed with lung cancer

Timeline

Screening 3 weeks

Treatment Varies

Follow Up initial measurement will occur 3 months after randomization

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing strategies to help people get lung cancer screening & diagnostic follow-up. Patients & clinicians will be interviewed after to gain insight into what works.

Who is the study for?

This trial is for patients aged 50-80 with a history of significant smoking who haven't been diagnosed with lung cancer and are non-adherent to lung cancer screening. It's also for clinicians in the University of Pennsylvania Health System who treat such patients and have not opted out.

What is being tested?

The study tests whether 'nudges' (gentle encouragements) can improve how well both doctors and patients stick to recommended lung cancer screenings. The effectiveness will be measured, followed by interviews to understand barriers or enhancers.

What are the potential side effects?

Since this trial involves behavioral interventions rather than medications, traditional side effects are not applicable. However, participants may experience increased healthcare engagement or changes in their interaction with healthcare providers.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 50-80 years old with a history of heavy smoking.

Select...

I have never been diagnosed with lung cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ initial measurement will occur 3 months after randomization

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~initial measurement will occur 3 months after randomization

This trial's timeline: 3 weeks for screening, Varies for treatment, and initial measurement will occur 3 months after randomization for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of completed annual LCS in patients with a negative baseline screen (Lung Imaging Reporting and Data System (Lung-RADS) 1 or 2).

Number of completed recommended diagnostic follow-up scans or procedures in patients with a positive baseline screen (Lung-RADS 3 or 4a).

Secondary study objectives

Reach

Other study objectives

Number of downstream imaging and diagnostic procedures

Number of lung cancer diagnoses

Rate of false-positive screens

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups

Experimental Treatment

Active Control

Group I: Patient Nudge OnlyExperimental Treatment1 Intervention

Patients in this arm will receive messaging designed to increase awareness about the importance of annual screening and recommended follow-up. Clinicians will receive usual care.

Group II: Clinician Nudge OnlyExperimental Treatment1 Intervention

Clinicians in this arm will not be prompted by a pended order when a patient is due for lung cancer screening or diagnostic follow-up. Patients will receive usual care.

Group III: Clinician Nudge + Patient NudgeExperimental Treatment2 Interventions

An EHR-prompt (pended order) will prompt clinicians in this arm when a patient is due for lung cancer screening or diagnostic follow-up. Patients in this arm will receive messaging designed to increase awareness about the importance of annual screening and recommended follow-up

Group IV: Usual care (no nudges)Active Control1 Intervention

Patients and clinicians in this arm will receive usual care.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Clinician Nudge

2020

N/A

~10730

Patient Nudge

2020